NANOCOMPOSIX, INC. — Department of Health and Human Services SBIR Phase I: We propose a lateral flow assay which will ultimately be able to detect loiasis, lymphatic

Description

We propose a lateral flow assay which will ultimately be able to detect loiasis, lymphatic filariasis, and onchocerciasis on a single strip. The test combines: Latest antigens discovered at the NIH upon sequencing of the L. loa genome, proprietary ultra-bright and color-tunable reporter particles, and data capture via a smart phone for mapping and monitoring filariases. In the Phase I, the assay will be configured for loiasis. There is a critical need for a commercial assay for loiasis, not just for individual case management, but also to aid the elimination programs aimed at lymphatic filariasis and onchocerciasis. Mass drugs administrations for these two diseases are not possible in areas coincident with Loa loa, due to potentially severe adverse events. The assay is designed to detect antigens, rather than circulating antibodies. In the Phase II, the assay will be configured to also detect lymphatic filariasis and onchocerciasis. An "app" will be provided to capture data quantitatively via smart phone, alongside with GPS coordinates, so as to map the status of all filariases in a global database. This proposal is endorsed by the Head of the Helminth Parasitology Section of the NIH.